NCT06251440

Brief Summary

Multifetal pregnancies are common in in vitro fertilization. Multifetal gestation increases maternal and fetal morbidity and mortality. We perform fetal reduction in our hospital by intra-thoracic injection of potassium chloride. This manuscript is description of our initial experience.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
108

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2018

Completed
5.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2023

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

January 31, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 9, 2024

Completed
Last Updated

February 9, 2024

Status Verified

February 1, 2024

Enrollment Period

5.2 years

First QC Date

January 31, 2024

Last Update Submit

February 8, 2024

Conditions

In Vitro Fertilization

Keywords

Fetal reductionMultifetal gestationIn Vitro fertilization

Outcome Measures

Primary Outcomes (1)

  • Transabdominal ultrasonography guided fetal reduction is safe and effective in first trimester

    To share initial experience of transabdominal multifetal pregnancy reduction (MFPR) in Nepal

    4.5 years

Interventions

Fetal ReductionDRUG

Under ultrasound guidance, intracardiac injection of 0.2 to 3.0 ml of 15% weight/volume (2 miliequivalent/mililiter ) potassium chloride (KCl) was administered via transabdominal route

Also known as: Selective fetal reduction

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant females with multiple pregnancy
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Multifetal pregnancies referred from the obstetrics and gynecology department of our hospital, different other hospitals and in vitro fertilization (IVF) centers across the country underwent ultrasound-guided transabdominal embryo/ fetal reduction procedure between February 2018 to April 2023 in our department.

You may qualify if:

  • pregnant females with multifetal gestation who opt to undergo fetal reduction

You may not qualify if:

  • who do not give consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prajwal Dahal

Kathmandu, Bagmati, Nepal, Nepal

Location

MeSH Terms

Interventions

Pregnancy Reduction, Multifetal

Intervention Hierarchy (Ancestors)

Abortion, InducedObstetric Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Sharma Poudel, MD

    Grande International Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 31, 2024

First Posted

February 9, 2024

Study Start

February 1, 2018

Primary Completion

April 30, 2023

Study Completion

April 30, 2023

Last Updated

February 9, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations

NE(1)